View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Jul. 31, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		20,492,643
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 20,042,000	$ 14,338,000
Accounts receivable, net of reserves of $785,000 and $797,000 in 2016 and 2015, respectively	911,000	1,052,000
Inventories, net	4,534,000	4,298,000
Other current assets	1,263,000	1,555,000
Total current assets	26,750,000	21,243,000
Property and equipment, net	1,380,000	1,631,000
Restricted cash and cash equivalents	350,000	350,000
Other assets	1,449,000	1,521,000
Intangibles, net	8,829,000	9,031,000
Goodwill	3,922,000	3,922,000
Total assets	42,680,000	37,698,000
Current liabilities:
Accounts payable and accrued expenses	6,585,000	6,687,000
Current portion of long-term obligations, net of discount	3,494,000	0
Joint venture purchase obligation		1,750,000
Total current liabilities	10,079,000	8,437,000
Deferred revenues	106,000	105,000
Long-term deferred rent and other	111,000	269,000
Long-term obligations, net of discount, less current portion	13,663,000	16,681,000
Total liabilities	23,959,000	25,492,000
Commitments and contingencies
Stockholders’ equity (deficit):
Series A 3.6% convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 13,500 shares issued; no shares outstanding in 2016 and 2015	0	0
Common stock, $0.001 par value; 75,000,000 shares authorized; 20,492,601 and 13,003,893 shares issued and outstanding in 2016 and 2015, respectively	20,000	13,000
Additional paid-in capital	386,845,000	368,214,000
Accumulated other comprehensive income	617,000	996,000
Accumulated deficit	(368,761,000)	(357,017,000)
Total stockholders’ equity	18,721,000	12,206,000
Total liabilities and stockholders’ equity	$ 42,680,000	$ 37,698,000

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Accounts receivable, reserves	$ 785,000	$ 797,000
Stockholders’ equity (deficit):
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	20,492,601	13,003,893
Common stock, shares outstanding (in shares)	20,492,601	13,003,893
Series A Preferred Stock [Member]
Stockholders’ equity (deficit):
Convertible preferred stock	3.60%	3.60%
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	13,500	13,500
Preferred stock, shares outstanding (in shares)	0	0

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Product revenues	$ 1,126,000	$ 1,614,000	$ 2,459,000	$ 2,516,000
Cost of product revenues	585,000	1,296,000	1,152,000	1,894,000
Gross profit	541,000	318,000	1,307,000	622,000
Development revenues:
Government contracts and other	1,699,000	1,847,000	3,284,000	3,291,000
Total development revenues	1,699,000	1,847,000	3,284,000	3,291,000
Operating expenses:
Research and development	5,247,000	6,048,000	9,374,000	10,012,000
Sales and marketing	889,000	654,000	1,924,000	1,493,000
General and administrative	2,328,000	2,793,000	4,614,000	5,292,000
Change in fair value of warrant liabilities		(13,122,000)	0	2,322,000
Total operating expenses	8,464,000	(3,627,000)	15,912,000	19,119,000
Operating (loss) income	(6,224,000)	5,792,000	(11,321,000)	(15,206,000)
Other income (expense):
Income (loss) on asset disposal		(1,000)	2,000	8,000
Loss on debt extinguishment		(260,000)	0	(260,000)
Interest income	2,000	3,000	4,000	3,000
Interest expense	(645,000)	(936,000)	(1,302,000)	(2,007,000)
Other income (expense), net	462,000	(148,000)	874,000	(47,000)
Total other expense	(181,000)	(1,342,000)	(422,000)	(2,303,000)
Net (loss) income	(6,405,000)	4,450,000	(11,743,000)	(17,509,000)
Beneficial conversion feature for convertible preferred stock				(661,000)
Net (loss) income allocable to common stockholders	$ (6,405,000)	$ 4,450,000	$ (11,743,000)	$ (18,170,000)
Net income (loss) per share allocable to common stockholders
Basic	$ (0.43)	$ 0.48	$ (0.84)	$ (2.22)
Diluted	$ (0.43)	$ 0.45	$ (0.84)	$ (2.22)
Weighted average shares used in calculating net income (loss) per share allocable to common stockholders
Basic	14,778,616	9,266,141	13,932,496	8,179,403
Diluted	14,778,616	9,824,538	13,932,496	8,179,403
Comprehensive (loss) income:
Net (loss) income	$ (6,405,000)	$ 4,450,000	$ (11,743,000)	$ (17,509,000)
Other comprehensive (loss) income – foreign currency translation adjustments	(130,000)	215,000	(379,000)	251,000
Comprehensive (loss) income	$ (6,535,000)	$ 4,665,000	$ (12,122,000)	$ (17,258,000)

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (11,743,000)	$ (17,509,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	574,000	510,000
Amortization of deferred financing costs and debt discount	468,000	500,000
Joint Venture acquisition obligation accretion	24,000	307,000
Provision for expired inventory	26,000	0
Change in fair value of warrants	0	2,322,000
Stock-based compensation expense	645,000	1,146,000
Loss on asset disposal	2,000	0
Loss on debt extinguishment	0	260,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	66,000	544,000
Inventories	(380,000)	730,000
Other current assets	137,000	(106,000)
Other assets	34,000	407,000
Accounts payable and accrued expenses	(431,000)	1,089,000
Deferred revenues	1,000	151,000
Long-term deferred rent	(158,000)	(139,000)
Net cash used in operating activities	(10,735,000)	(9,788,000)
Cash flows from investing activities:
Purchases of property and equipment	(105,000)	(497,000)
Expenditures for intellectual property	0	(13,000)
Net cash used in investing activities	(105,000)	(510,000)
Cash flows from financing activities:
Principal payments on long-term obligations	0	(25,032,000)
Proceeds from long-term obligations	0	17,700,000
Debt issuance costs and loan fees	0	(1,854,000)
Joint Venture purchase payments	(1,774,000)	(1,123,000)
Proceeds from exercise of employee stock options and warrants	0	4,986,000
Proceeds from sale of common stock, net	18,179,000	24,930,000
Dividends paid on preferred stock	0	(75,000)
Net cash provided by financing activities	16,405,000	19,532,000
Effect of exchange rate changes on cash and cash equivalents	139,000	(14,000)
Net increase in cash and cash equivalents	5,704,000	9,220,000
Cash and cash equivalents at beginning of period	14,338,000	14,622,000
Cash and cash equivalents at end of period	20,042,000	23,842,000
Cash paid during period for:
Interest	805,000	1,202,000
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock into common stock	0	10,000
Declared dividend related to preferred stock	$ 0	$ 3,000

Basis of Presentation

6 Months Ended

Jun. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation

1.	Basis of Presentation

Our accompanying unaudited consolidated condensed financial statements as of June 30, 2016 and for the three and six months ended June 30, 2016 and 2015 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2015 has been derived from the audited financial statements at December 31, 2015, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included. Operating results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on March 11, 2016.

On May 10, 2016, following stockholder and Board approval, an amendment (the “Amendment”) to the Company’s amended and restated certificate of incorporation, as amended was filed and declared effective, which Amendment effectuated a one-for-fifteen (1:15) reverse stock split of the Company’s (i) outstanding common stock, and (ii) common stock reserved for issuance upon exercise of outstanding warrants and options (the “1:15 Reverse Stock Split”). Upon effectiveness of the 1:15 Reverse Stock Split, the number of shares of the Company’s common stock (x) issued and outstanding decreased from approximately 200 million shares (as of May 10, 2016) to approximately 13.3 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 16 million shares to approximately 1.1 million shares, and (z) reserved but unallocated under our current equity incentive plans (including the stockholder-approved share increase to the Company’s 2014 Equity Incentive Plan) decreased from approximately 6.5 million common shares to approximately 0.4 million common shares. In connection with the 1:15 Reverse Stock Split, the Company also decreased the total number of its authorized shares of common stock from 290 million to 75 million. The number of authorized shares of preferred stock remained unchanged. Following the 1:15 Reverse Stock Split, certain reclassifications have been made to the prior periods’ financial statements to conform to the current period's presentation. The Company adjusted shareholders’ equity to reflect the 1:15 Reverse Stock Split by reclassifying an amount equal to the par value of the additional shares arising from the split from common stock to the Additional Paid-in Capital during the first quarter of fiscal 2016, resulting in no net impact to shareholders' equity on our consolidated balance sheets. The Company’s shares of common stock commenced trading on a split-adjusted basis on May 12, 2016. Proportional adjustments for the reverse stock split were made to the Company's outstanding stock options, warrants and equity incentive plans for all periods presented.

The following table provides a brief description of recent accounting pronouncements that had and/or could have a material impact on the Company’s consolidated condensed financial statements. The Company is currently evaluating the impact of adopting the following standards on its consolidated financial statements.

New Accounting Standards Issued But Not Yet Effective

ASU Number and Name	Description	Date of Adoption
2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting	The standard simplifies the following aspects of accounting for share-based payments awards: accounting for income taxes, classification of excess tax benefits on the statement of cash flows, forfeitures, statutory tax withholding requirements, classification of awards as either equity or liabilities and classification of employee taxes paid on statement of cash flows when an employer withholds shares for tax-withholding purposes. Transition method: Various.	January 1, 2017. Early adoption is permitted.
2016-02, Leases (Topic 842)	The standard creates Topic 842, Leases which supersedes Topic 840, Leases, and introduces a lessee model that brings substantially all leases onto the balance sheet while retaining most of the principles of the existing lessor model in U.S. GAAP and aligning many of those principles with ASC 606, Revenue from Contracts with Customers. Transition method: modified retrospective approach with certain practical expedients.	January 1, 2019. Early adoption is permitted.
2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory	The standard replaces the current lower of cost or market test with a lower of cost or net realizable value test. Transition method: prospectively.	January 1, 2017. Early adoption is permitted.
2014-09, Revenue from Contracts with Customers (Topic 606)	The standard provides a single and comprehensive revenue recognition model for all contracts with customers to improve comparability. The revenue standard contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The standard requires an entity to recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. Transition method: a full retrospective or modified retrospective approach.	January 1, 2018 (as deferred by ASU No. 2015-14). Earlier application is permitted only as of January 1, 2017.
2016-08, Revenue from Contracts with Customers (Topic 606) — Principal versus Agent Considerations (Reporting Revenue Gross versus Net)	The standard clarifies how an entity should identify the unit of accounting for the principal versus agent evaluation and apply the control principle to certain types of arrangements. The amendments also re-frame the indicators to focus on evidence that an entity is acting as a principal rather than as an agent, revise existing examples and add new ones. Transition method: a full retrospective or modified retrospective approach.	January 1, 2018 (as deferred by ASU No. 2015-14). Earlier application is permitted only as of January 1, 2017.
2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing	This standard clarifies the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. This standard reduces the cost and complexity of applying Topic 606 to the identification of promised goods or services, and it also includes implementation guidance on licensing. Transition method: a full retrospective or modified retrospective approach.	January 1, 2018 (as deferred by ASU No. 2015-14). Earlier application is permitted only as of January 1, 2017.
2016-12, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing	This standard addresses narrow-scope improvements to the guidance on collectability, noncash consideration, and completed contracts at transition as well as providing a practical expedient for contract modifications.	January 1, 2018 (as deferred by ASU No. 2015-14). Earlier application is permitted only as of January 1, 2017.
2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.	The amendments in this update will require management to assess, at each annual and interim reporting period, the entity’s ability to continue as a going concern and, if management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued, to disclose in the notes to the entity’s financial statements the principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern, management’s evaluation of their significance, and management’s plans that alleviated or are intended to alleviate substantial doubt about the entity’s ability to continue as a going concern.	January 1, 2017. Early adoption is permitted.

Use of Estimates

6 Months Ended

Jun. 30, 2016

Use Of Estimates [Abstract]

Use of Estimates

2.	Use of Estimates

The preparation of Consolidated Condensed Financial Statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, valuing warrants, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the joint venture, and valuing allowances for doubtful accounts and inventories.

Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the Consolidated Condensed Financial Statements in the periods they are determined to be necessary.

Liquidity

6 Months Ended

Jun. 30, 2016

Liquidity [Abstract]

Liquidity

We incurred net losses of $6.4 million and $11.7 million for the three and six months ended June 30, 2016, respectively, and incurred net income of $4.5 million and net losses of $17.5 million for the three and six months ended June 30, 2015, respectively. We have an accumulated deficit of $369 million as of June 30, 2016. Additionally, we have used net cash of $10.7 million and $9.8 million to fund our operating activities for the six months ended June 30, 2016 and 2015, respectively.

To date, these operating losses have been funded primarily from outside sources of invested capital including our recently completed Rights Offering (discussed below), our At the Market equity facility, Loan and Security Agreement and gross profits. We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations.

On June 15, 2016, the Company closed a Rights Offering originally filed under Form S-1 registration statement in April 2016. Pursuant to the Rights Offering, the Company sold an aggregate of 6,704,852 units consisting of a total of 6,704,852 shares of common stock and 3,352,306 warrants, with each warrant exercisable for one share of common stock at an exercise price of $3.06 per share, resulting in total gross proceeds to Cytori of $17.1 million. See Note 12 for further discussion on the June 2016 Rights Offering.

The Company continues to seek additional capital through product revenues, strategic transactions, including extension opportunities under the awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives.

Should we be unable to raise additional cash from outside sources, this will have an adverse impact on our operations.

Transactions with Olympus Corporation

6 Months Ended

Jun. 30, 2016

Business Combinations [Abstract]

Transactions with Olympus Corporation

4.	Transactions with Olympus Corporation

Under our Joint Venture Termination Agreement (“Termination Agreement”), dated May 8, 2013, with Olympus Corporation (“Olympus”), we were required to pay Olympus a total purchase price of $6 million within two years of the date of the Termination Agreement. Pursuant to amendments to the Joint Venture Termination Agreement, dated April 30, 2015 and January 8, 2016, the Company’s repayment obligations were extended through May 8, 2016. We made payments under the Termination Agreement totaling approximately $4.2 million through December 31, 2015, as well as separate payments of $0.5 million each in January 2016 and April 2016, and paid the remaining balance of $0.8 million before the May 8, 2016 due date. There were no outstanding obligations to Olympus as of June 30, 2016.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Long-term Debt

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Long-term Debt

5.	Long-term Debt

On May 29, 2015, we entered into the Loan Agreement with Oxford Finance LLC, pursuant to which it funded an aggregate principal amount of $17.7 million (“Term Loan”), subject to the terms and conditions set forth in the Loan Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan Agreement, we were previously required to make interest only payments through June 1, 2016 and thereafter we were required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term loan through June 1, 2019, the maturity date. On February 23, 2016, we received an acknowledgement and agreement from Oxford related to the positive data on our U.S. ACT-OA clinical trial. As a result, pursuant to the Loan Agreement, the period for which the Company is required to make interest-only payments was extended from July 1, 2016 to January 1, 2017. All unpaid principal and interest with respect to the Term Loan is due and payable in full on June 1, 2019. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment fee in an aggregate amount equal to approximately $1.1 million. In connection with the Term Loan, on May 29, 2015, we issued to the Lender warrants to purchase an aggregate of 94,441 shares of our common stock at an exercise price of $10.35 per share. These warrants are exercisable on or after November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified.

In connection with the Loan Agreement, we prepaid all outstanding amounts under our prior loan agreement with Oxford and Silicon Valley Bank, at which time the Company’s obligations under the prior loan agreement immediately terminated. The Company paid to the prior agent and the prior lenders (Oxford and Silicon Valley Bank) approximately $25.4 million, consisting of the then outstanding principal balance due of approximately $23.4 million, accrued but unpaid interest of approximately $0.2 million, final payment and other agency fees of approximately $1.8 million and other customary lender fees and expenses.

For Oxford, we accounted for this Term Loan as a debt modification. The Company retired $3.1 million of the principal of the previous loan and the corresponding unamortized fees were expensed. The remaining fees of $0.8 million were recorded as debt discount, and along with the new loan fees, will be amortized as an adjustment of interest expense using the effective interest method. For Silicon Valley Bank, which did not participate in the Term Loan, the payoff of the loan was accounted for as debt extinguishment. Accordingly, a total loss on debt extinguishment of $0.3 million was recorded in the second quarter of 2015, which includes the unamortized fees and discounts along with final payment fees.

We allocated the aggregate proceeds of the Term Loan between the warrants and the debt obligations based on their relative fair values. The fair value of the warrants issued to the Lender was calculated utilizing the Black-Scholes option pricing model. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and risk-free interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free interest rate for period within the contractual life of the warrant is based on the U.S. Treasury yield in effect at the time of grant. We will amortize the relative fair value of the warrants at the issuance date as a discount of $0.8 million over the term of the loan using the effective interest method, with an effective interest rate of 14.95%. The Term Loan is collateralized by a security interest in substantially all of the Company’s existing and after-acquired assets, subject to certain exceptions set forth in the Loan Agreement and excluding its intellectual property assets, which are subject to a negative pledge.

Revenue Recognition

6 Months Ended

Jun. 30, 2016

Revenue Recognition [Abstract]

Revenue Recognition

6.	Revenue Recognition

Concentration of Significant Customers

Two distributors and two direct customers comprised 76% of our revenue recognized for the six months ended June 30, 2016. Two distributors and one direct customer accounted for 75% of total outstanding accounts receivable (excluding receivables from U.S. Department and Human Service’s Biomedical Advanced Research and Development Authority (BARDA)) as of June 30, 2016.

Two distributors and three direct customers comprised 68% of our revenue recognized for the six months ended June 30, 2015. Two direct customers accounted for 73% of total outstanding accounts receivable as of June 30, 2015.

Product revenues, classified by geographic location, are as follows:

	Three months ended										Six months ended
	June 30, 2016					June 30, 2015					June 30, 2016					June 30, 2015
	Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total
Americas	$	356,000		31	%	$	272,000		17	%	$	591,000		24	%	$	477,000		19	%
Japan		690,000		61	%		352,000		22	%		1,657,000		67	%		957,000		38	%
EMEA		74,000		7	%		328,000		20	%		205,000		8	%		416,000		17	%
Asia Pacific		6,000		1	%		662,000		41	%		6,000		1	%		666,000		26	%
Total product revenues	$	1,126,000		100	%	$	1,614,000		100	%	$	2,459,000		100	%	$	2,516,000		100	%

Research and Development

We earn revenue for performing tasks under research and development agreements with governmental agencies like the Biomedical Advanced Research and Development Authority (“BARDA”). Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $1.7 million and $3.3 million in BARDA revenue for the three and six months ended June 30, 2016, respectively, as compared to $1.8 million and $3.3 million for the three and six months ended June 30, 2015, respectively.

Inventories

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Inventories

7.	Inventories

Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.

Inventories consisted of the following:

	June 30, 2016		December 31, 2015
Raw materials	$	972,000	$	1,009,000
Work in process		1,205,000		816,000
Finished goods		2,357,000		2,473,000
	$	4,534,000	$	4,298,000

Earnings per Share

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Earnings per Share

8.	Earnings per Share

Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented.

We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the three and six month periods ended June 30, 2016 and six month period ended June 30, 2015, as their inclusion would be antidilutive. We have included 0.6 million dilutive securities for the purposes of calculating earnings per share for the three months ended June 30, 2015. Potentially dilutive common shares excluded from the calculations of diluted loss per share were 4.4 million for the six month periods ended June 30, 2016 and 3.7 million for the six month period ended June 30, 2015, respectively.

The following securities that could potentially decrease net loss per share in the future are not included in the determination of diluted loss per share as they are anti-dilutive:

	For the three months ended June 30,				For the six months ended June 30,
	2016		2015		2016		2015
Outstanding stock options		803,507		528,429		803,507		570,214
Outstanding warrants		3,571,765		2,542,255		3,571,765		3,058,868
Restricted stock		17,960		41,677		17,960		41,677

Commitments and Contingencies

6 Months Ended

Jun. 30, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

9.	Commitments and Contingencies

We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of June 30, 2016, we have clinical research study obligations of $4.8 million ($3.8 million of which are expected to be complete within a year). Should the timing of the clinical trials change, the timing of the payment of these obligations would also change.

We lease facilities for our headquarters office location as well as international office locations. As of June 30, 2016, we have remaining lease obligations of $3.1 million ($2.3 million of which are expected to be completed within a year).

We are party to an agreement with Roche Diagnostics Corporation which requires us to make certain product purchase minimums. Pursuant to the agreement, as of June 30, 2016, we have a minimum purchase obligation of $5.9 million, $1.3 million of which is expected to be completed within a year.

We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.

See Note 4 for a discussion of our commitments and contingencies related to our transactions with Olympus.

Fair Value Measurements

6 Months Ended

Jun. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

10.	Fair Value Measurements

Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.

As of June 30, 2016 and as of December 31, 2015, the Company did not have any assets or liabilities measured at fair value presented on the Company’s balance sheets.

Warrants with exercise price reset features (down-round protection) were accounted for as liabilities, with changes in the fair value included in net loss for the respective periods. Because some of the inputs to our valuation model were either not observable or were not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability was classified as Level 3 in the fair value hierarchy. All of these warrants were cashless exercised on or before December 31, 2015.

Fair Value

6 Months Ended

Jun. 30, 2016

Financial Instruments Financial Liabilities Balance Sheet Groupings [Abstract]

Fair Value

11.	Fair Value

Financial Instruments

We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at June 30, 2016 and December 31, 2015, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.

We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available. If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.

At June 30, 2016 and December 31, 2015, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows:

	June 30, 2016				December 31, 2015
	Fair Value		Carrying Value		Fair Value		Carrying Value
Long-term debt	$	17,187,000	$	17,157,000	$	16,844,000	$	16,681,000

Carrying value is net of debt discount of $1.6 million and $2.1 million as of June 30, 2016 and December 31, 2015, respectively.

The fair value of debt is classified as Level 3 in the fair value hierarchy as some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

6 Months Ended

Jun. 30, 2016

Stockholders Equity Note [Abstract]

Stockholders' Equity

12.	Stockholders’ Equity

Preferred Stock

We have authorized 5 million shares of $0.001 par value preferred stock. Our Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock that had been issued at June 30, 2016 and December 31, 2015, none of which were outstanding as of either date.

All outstanding shares of the Series A 3.6% Convertible Preferred Stock were converted into common stock during the fourth quarter of 2014 and the first quarter of 2015 at the option of the holders. The fair value of the common stock into which the Series A 3.6% Convertible Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a dividend to the preferred stockholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common stockholders. Certain shares of Series A 3.6% Convertible Preferred Stock were not convertible until stockholder approval, which occurred in January 2015. As a result, a dividend for the beneficial conversion feature of $0.7 million was recorded during the quarter ended March 31, 2015.

In connection with the 3.6% Convertible Preferred Stock outstanding at December 31, 2014, we declared a cash dividend of $0.08 million. The cash dividend was paid in January and April 2015.

Common Stock

In May 2015, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25 million of units, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock, in a registered direct offering. The purchase and sale of the units took place in two separate closings. At the initial closing, which took place on May 8, 2015, the Company received approximately $17.4 million in net proceeds from the sale of units. The second closing of the purchase and sale of the units occurred on August 27, 2015 upon satisfaction of certain conditions, including, without limitation, stockholder vote, and the Company received approximately $2.1 million in net proceeds from the sale of 500,000 units of the 1,000,000 units available for sale at the second closing.

On December 17, 2015, the Company and the holders of October 2014 warrants agreed to amend the October 2014 Warrants pursuant to an Amendment to Common Stock Purchase Warrant (the “2014 Amendment”). Also on December 17, 2015, the Company and the holders of the May 2015 Warrants and the August 2015 Warrants (collectively the “2015 Warrants”) agreed to amend the 2015 Warrants pursuant to an Amendment to Series A-1 Warrant to Purchase Common Stock and Amendment to Series A-2 Warrant to Purchase Common Stock, respectively (the “2015 Amendment” and, together with the 2014 Amendment, the “Warrant Amendments”). The Warrant Amendments provide that the holders may exercise their warrants on a “cashless exercise” basis in whole on or prior to December 31, 2015, whereby each exercising holder of the amended 2015 Warrants would receive 0.75 shares for each warrants share exercised and each exercising holder of the amended 2014 Warrants would receive 0.69 shares for each warrant share exercised. In addition, the Warrant Amendments removed certain provisions which provided that the exercise price of the Warrants would be reset in the event of certain equity issuances by the Company for a price below the exercise price of the Warrants as of the time of such issuance. All 2014 Warrants and all 2015 Warrants were cashless exercised on or before December 31, 2015.

From January 1, 2016 and through June 30, 2016, we sold 766,382 shares of our common stock under an at-the-market offering program (“ATM”), receiving total net proceeds of approximately $2.7 million.

Pursuant to a registration statement on Form S-1, originally filed on April 6, 2016, as amended (the “Registration Statement”), and declared effective by the U.S. Securities and Exchange Commission (“SEC”) on May 26, 2016, and related prospectus (as supplemented), the Company registered, offered and sold to its participating stockholders of record as of the announced May 20, 2016 record date, one non-transferable subscription right for each share of common stock held by each stockholder as of the record date (the “Rights Offering”). Each right entitled the holder thereof to purchase one unit at the subscription price of $2.55 per unit, composed of one share of common stock and 0.5 of a warrant, with each whole warrant exercisable to purchase one share of common stock at an exercise price of $3.06 per share for 30 months from the date of issuance. Pursuant to the Rights Offering, which closed on June 15, 2016, the Company sold an aggregate of 6,704,852 units, resulting in total net proceeds to the Company of $15.3 million, respectively. The warrants issued pursuant to the Rights Offering are currently listed on NASDAQ under the symbol “CTYXW.” The warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration if the Company’s common stock closes above $7.65 per share for 10 consecutive trading days.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Basis of Presentation (Policies)

6 Months Ended

Jun. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation

New Accounting Standards Issued But Not Yet Effective

ASU Number and Name	Description	Date of Adoption
2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting	The standard simplifies the following aspects of accounting for share-based payments awards: accounting for income taxes, classification of excess tax benefits on the statement of cash flows, forfeitures, statutory tax withholding requirements, classification of awards as either equity or liabilities and classification of employee taxes paid on statement of cash flows when an employer withholds shares for tax-withholding purposes. Transition method: Various.	January 1, 2017. Early adoption is permitted.
2016-02, Leases (Topic 842)	The standard creates Topic 842, Leases which supersedes Topic 840, Leases, and introduces a lessee model that brings substantially all leases onto the balance sheet while retaining most of the principles of the existing lessor model in U.S. GAAP and aligning many of those principles with ASC 606, Revenue from Contracts with Customers. Transition method: modified retrospective approach with certain practical expedients.	January 1, 2019. Early adoption is permitted.
2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory	The standard replaces the current lower of cost or market test with a lower of cost or net realizable value test. Transition method: prospectively.	January 1, 2017. Early adoption is permitted.
2014-09, Revenue from Contracts with Customers (Topic 606)	The standard provides a single and comprehensive revenue recognition model for all contracts with customers to improve comparability. The revenue standard contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The standard requires an entity to recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. Transition method: a full retrospective or modified retrospective approach.	January 1, 2018 (as deferred by ASU No. 2015-14). Earlier application is permitted only as of January 1, 2017.
2016-08, Revenue from Contracts with Customers (Topic 606) — Principal versus Agent Considerations (Reporting Revenue Gross versus Net)	The standard clarifies how an entity should identify the unit of accounting for the principal versus agent evaluation and apply the control principle to certain types of arrangements. The amendments also re-frame the indicators to focus on evidence that an entity is acting as a principal rather than as an agent, revise existing examples and add new ones. Transition method: a full retrospective or modified retrospective approach.	January 1, 2018 (as deferred by ASU No. 2015-14). Earlier application is permitted only as of January 1, 2017.
2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing	This standard clarifies the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. This standard reduces the cost and complexity of applying Topic 606 to the identification of promised goods or services, and it also includes implementation guidance on licensing. Transition method: a full retrospective or modified retrospective approach.	January 1, 2018 (as deferred by ASU No. 2015-14). Earlier application is permitted only as of January 1, 2017.
2016-12, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing	This standard addresses narrow-scope improvements to the guidance on collectability, noncash consideration, and completed contracts at transition as well as providing a practical expedient for contract modifications.	January 1, 2018 (as deferred by ASU No. 2015-14). Earlier application is permitted only as of January 1, 2017.
2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.	The amendments in this update will require management to assess, at each annual and interim reporting period, the entity’s ability to continue as a going concern and, if management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued, to disclose in the notes to the entity’s financial statements the principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern, management’s evaluation of their significance, and management’s plans that alleviated or are intended to alleviate substantial doubt about the entity’s ability to continue as a going concern.	January 1, 2017. Early adoption is permitted.

Use of Estimates

Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2016

Revenue Recognition [Abstract]

Product Revenues by Geographic Location

Product revenues, classified by geographic location, are as follows:

	Three months ended										Six months ended
	June 30, 2016					June 30, 2015					June 30, 2016					June 30, 2015
	Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total			Product Revenues		% of Total
Americas	$	356,000		31	%	$	272,000		17	%	$	591,000		24	%	$	477,000		19	%
Japan		690,000		61	%		352,000		22	%		1,657,000		67	%		957,000		38	%
EMEA		74,000		7	%		328,000		20	%		205,000		8	%		416,000		17	%
Asia Pacific		6,000		1	%		662,000		41	%		6,000		1	%		666,000		26	%
Total product revenues	$	1,126,000		100	%	$	1,614,000		100	%	$	2,459,000		100	%	$	2,516,000		100	%

Inventories (Tables)

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Inventory

Inventories consisted of the following:

	June 30, 2016		December 31, 2015
Raw materials	$	972,000	$	1,009,000
Work in process		1,205,000		816,000
Finished goods		2,357,000		2,473,000
	$	4,534,000	$	4,298,000

Earnings per Share (Tables)

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Schedule of Anti-dilutive Securities Not Included in Determination of Diluted Loss per Share

The following securities that could potentially decrease net loss per share in the future are not included in the determination of diluted loss per share as they are anti-dilutive:

	For the three months ended June 30,				For the six months ended June 30,
	2016		2015		2016		2015
Outstanding stock options		803,507		528,429		803,507		570,214
Outstanding warrants		3,571,765		2,542,255		3,571,765		3,058,868
Restricted stock		17,960		41,677		17,960		41,677

Fair Value (Tables)

6 Months Ended

Jun. 30, 2016

Financial Instruments Financial Liabilities Balance Sheet Groupings [Abstract]

Fair Value and Carrying Value of Long-term Debt

At June 30, 2016 and December 31, 2015, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows:

	June 30, 2016				December 31, 2015
	Fair Value		Carrying Value		Fair Value		Carrying Value
Long-term debt	$	17,187,000	$	17,157,000	$	16,844,000	$	16,681,000

Basis of Presentation (Details)	May 10, 2016 shares	Jun. 30, 2016 shares	Jun. 15, 2016 shares	Mar. 31, 2016 shares	Dec. 31, 2015 shares
Subsequent Event [Line Items]
Reverse stock split of common stock	15
Common stock, shares outstanding (in shares)	13,300,000	20,492,601	6,704,852	200,000,000	13,003,893
Number of shares callable by warrants (in shares)	1,100,000		1	16,000,000
Common stock, shares authorized (in shares)	75,000,000	75,000,000		290,000,000	75,000,000
2014 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Number of shares callable by warrants (in shares)	400,000			6,500,000

Liquidity (Details) - USD ($)		3 Months Ended		6 Months Ended
Liquidity (Details) - USD ($)	Jun. 16, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 15, 2016	May 10, 2016	Mar. 31, 2016	Dec. 31, 2015
Liquidity [Abstract]
Net loss		$ (6,405,000)	$ 4,450,000	$ (11,743,000)	$ (17,509,000)
Accumulated deficit		$ 368,761,000		368,761,000					$ 357,017,000
Net cash used in operating activities				$ 10,735,000	$ 9,788,000
Common stock issued (in shares)	6,704,852
Common stock, shares outstanding (in shares)		20,492,601		20,492,601		6,704,852	13,300,000	200,000,000	13,003,893
Each unit consist of number of warrant	3,352,306
Number of shares callable by warrants (in shares)						1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)						$ 3.06
Proceeds from issuance warrants	$ 17,100,000

Transactions with Olympus Corporation (Details) - USD ($)		6 Months Ended
	Apr. 30, 2015	Jun. 30, 2016
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Total purchase price	$ 6,000,000
Purchase price payment agreement term		2 years
Amendment One to Joint Venture Termination Agreement [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Purchase price payment termination agreement total	4,200,000
Purchase price principal amount payable on January 31, 2016	500,000
Purchase price principal amount payable on April 30, 2016	500,000
Purchase price principal amount and accrued interest payable on May 8, 2016	$ 800,000
Purchase price payable obligations outstanding balance.		$ 0

Long-term Debt (Details) - USD ($)		3 Months Ended		6 Months Ended
Long-term Debt (Details) - USD ($)	May 29, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 15, 2016	May 10, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Number of shares callable by warrants (in shares)						1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)						$ 3.06
Repayment of long term debt				$ 0	$ 25,032,000
Loss on debt extinguishment			$ (260,000)	$ 0	$ (260,000)
LIBOR [Member] \| Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate	1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination date				May 29, 2015
Original loan amount	$ 17,700,000
Basis variable rate	7.95%
Maturity date				Jun. 01, 2019
Fees amount associated with loan	$ 1,100,000
Date from which warrants are exercisable				Nov. 30, 2015
Number of shares callable by warrants (in shares)	94,441
Warrant exercise price (in dollars per share)	$ 10.35
Warrant expiration date				May 29, 2025
Repayment of long term debt	$ 25,400,000
Term Loan remaining balance at date of Amendment	23,400,000
Accrued but unpaid interest	200,000
Final payment fee	1,800,000
Principal amount of previous loan retired	3,100,000
Unamortized debt discount	$ 800,000
Loss on debt extinguishment		$ 300,000
Effective interest rate	14.95%
Term Loan [Member] \| Final Payment [Member]
Debt Instrument [Line Items]
Fees amount associated with loan	$ 800,000
Minimum \| Term Loan [Member]
Debt Instrument [Line Items]
Interest rate	8.95%

Revenue Recognition (Details)	3 Months Ended		6 Months Ended
Revenue Recognition (Details)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) Distributor Customer	Jun. 30, 2015 USD ($) Distributor Customer
Concentration Risk [Line Items]
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Revenues	$ 1,126,000	$ 1,614,000	$ 2,459,000	$ 2,516,000
BARDA Contract [Member]
Concentration Risk [Line Items]
Revenue recognized	$ 1,700,000	$ 1,800,000	$ 3,300,000	$ 3,300,000
Americas [Member]
Concentration Risk [Line Items]
Concentration risk percentage	31.00%	17.00%	24.00%	19.00%
Revenues	$ 356,000	$ 272,000	$ 591,000	$ 477,000
Japan [Member]
Concentration Risk [Line Items]
Concentration risk percentage	61.00%	22.00%	67.00%	38.00%
Revenues	$ 690,000	$ 352,000	$ 1,657,000	$ 957,000
EMEA [Member]
Concentration Risk [Line Items]
Concentration risk percentage	7.00%	20.00%	8.00%	17.00%
Revenues	$ 74,000	$ 328,000	$ 205,000	$ 416,000
Asia Pacific [Member]
Concentration Risk [Line Items]
Concentration risk percentage	1.00%	41.00%	1.00%	26.00%
Revenues	$ 6,000	$ 662,000	$ 6,000	$ 666,000
Customer Concentration Risk [Member] \| Revenue Recognized [Member]
Concentration Risk [Line Items]
Number of distributors \| Distributor			2	2
Number of customers \| Customer			2	3
Concentration risk percentage			76.00%	68.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of distributors \| Distributor			2
Number of customers \| Customer			1	2
Concentration risk percentage			75.00%	73.00%

Inventories (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 972,000	$ 1,009,000
Work in process	1,205,000	816,000
Finished goods	2,357,000	2,473,000
Inventory, net	$ 4,534,000	$ 4,298,000

Earnings per Share (Details) - shares	3 Months Ended		6 Months Ended
Earnings per Share (Details) - shares	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities included for the calculating earnings per share (in shares)		600,000
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)			4,400,000	3,700,000
Outstanding Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	803,507	528,429	803,507	570,214
Outstanding Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	3,571,765	2,542,255	3,571,765	3,058,868
Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	17,960	41,677	17,960	41,677

Commitments and Contingencies (Details) $ in Millions	Jun. 30, 2016 USD ($)
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase obligation	$ 4.8
Purchase obligation, due in next twelve months	3.8
Operating Lease Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation	3.1
Contractual obligation, due in next twelve months	2.3
Roche Diagnostics Corporation [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase obligation	5.9
Purchase obligation, due in next twelve months	$ 1.3

Fair Value (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	$ 17,187,000	$ 16,844,000
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	17,157,000	16,681,000
Debt discount	$ 1,600,000	$ 2,100,000

Stockholders' Equity (Details)				1 Months Ended	6 Months Ended		12 Months Ended
Stockholders' Equity (Details)	Jun. 16, 2016 shares	Aug. 27, 2015 USD ($) shares	May 08, 2015 USD ($)	May 31, 2015 USD ($) Closing shares	Jun. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2015 USD ($)	Dec. 31, 2015 $ / shares shares	Dec. 31, 2014 USD ($)	Jun. 15, 2016 $ / shares shares	May 10, 2016 shares	Mar. 31, 2016 shares	Dec. 17, 2015 shares	Mar. 31, 2015 USD ($)
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)					5,000,000
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.001
Common Stock [Abstract]
Number of shares callable by warrants (in shares)									1	1,100,000	16,000,000
Common stock issued (in shares)	6,704,852
Common stock, shares authorized (in shares)					75,000,000		75,000,000			75,000,000	290,000,000
Proceeds from sale of common stock, net \| $					$ 18,179,000	$ 24,930,000
Each unit consist of number of warrant	3,352,306
Warrant exercise price (in dollars per share) \| $ / shares									$ 3.06
Securities Purchase Agreement [Member]
Common Stock [Abstract]
Common stock issued, value \| $				$ 25,000,000
Number of closings \| Closing				2
Securities Purchase Agreement [Member] \| Initial Closing [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $			$ 17,400,000
Securities Purchase Agreement [Member] \| Second Closing [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $		$ 2,100,000
Common stock issued (in shares)		500,000
Common stock, shares authorized (in shares)		1,000,000
Common Stock [Member] \| Securities Purchase Agreement [Member]
Common Stock [Abstract]
Number of shares callable by warrants (in shares)				1
Number of shares callable by each warrant (in shares)				1
Warrants [Member] \| Securities Purchase Agreement [Member]
Common Stock [Abstract]
Number of shares callable by warrants (in shares)				1
ATM [Member]
Common Stock [Abstract]
Common stock issued (in shares)					766,382
Proceeds from sale of common stock, net \| $					$ 2,700,000
Series A Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)					5,000,000		5,000,000
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.001		$ 0.001
Preferred stock, shares issued (in shares)					13,500		13,500
Convertible preferred stock					3.60%		3.60%	3.60%
Series A Preferred Stock [Member] \| Dividend Paid [Member]
Preferred Stock [Abstract]
Dividends payable \| $													$ 700,000
Series A Preferred Stock [Member] \| Dividend Declared [Member]
Preferred Stock [Abstract]
Dividends payable \| $								$ 80,000
Common Stock [Member]
Common Stock [Abstract]
Number of shares callable by warrants (in shares)					1
Common stock issued (in shares)					6,704,852
Common Stock Subscription Price \| $ / shares					$ 2.55
Each unit consist of number of common stock					1
Each unit consist of number of warrant					0.5
Warrant exercise price (in dollars per share) \| $ / shares					$ 3.06
Period exercisable from the date of issuance					30 months
Gross proceeds from private placement of stock \| $					$ 15,300,000
Redemption price of warrant prior to expiration \| $ / shares					$ 0.01
Common stock price per share for warrant redemption \| $ / shares					$ 7.65
Number of consecutive trading days for warrant redemption					10 days
Common Stock [Member] \| 2015 Amendment [Member]
Common Stock [Abstract]
Number of shares callable by each warrant (in shares)												0.75
Common Stock [Member] \| 2014 Amendment [Member]
Common Stock [Abstract]
Number of shares callable by each warrant (in shares)												0.69